International Breast Cancer Centre (IBCC)
Hospital
Location:
Barcelona,
Spain (ES)
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024)
Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al.
Journal article
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023)
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al.
Journal article
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis (2022)
Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, et al.
Conference contribution
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (2022)
Huang M, Haiderali A, Fox GE, Frederickson A, Cortes J, Fasching P, O'Shaughnessy J
Journal article, Review article